Term ends May 16, 2040 · Medium confidence
20-year base term ends May 16, 2040
Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 11,478,436), so the cap could be lower.
May 16, 2020
May 16, 2040
Aug 30, 2022
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 3 maintenance fees is paid so far. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts May 16, 2020, when application 16/876,020, the earliest non-provisional in its chain, was filed (this one was filed Dec 20, 2021) | May 16, 2040 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 11,478,436) | resolves to May 16, 2040, no earlier than this term, so no change | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | May 16, 2040 | Medium confidence |
This family
| US 11,090,278 | In force May 2040 | May 2040 |
| US 11,464,752 | In force May 2040 | May 2040 |
| US 11,241,400 | In force May 2040 | May 2040 |
| US 11,426,369 | this patent May 2040 | May 2040 |
| US 11,478,436 | In force no later than May 2040 | no later than May 2040 |
| US 11,571,398 | In force no later than May 2040 | no later than May 2040 |
| Application 17/962,626 | Pending not computed | not computed |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Dec 21, 2021 Reel 58442, frame 350 | Ahmed, Shahid | Nexus Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| May 8, 2023 Reel 63568, frame 369 | Nexus Pharmaceuticals, LLC; Nexpharm Parent Holdco, LLC; Isopro Holdings, LLC | Sagent Group, LLC | Security Interest |
| May 24, 2023 Reel 63752, frame 975 | Nexus Pharmaceuticals, Inc. | Nexus Pharmaceuticals II, LLC | Statutory Conversion |
| May 26, 2023 Reel 63789, frame 675 | Nexus Pharmaceuticals II, LLC | Nexus Pharmaceuticals, LLC | Change of Name |
| Jun 3, 2024 reel/frame not recorded | Sagent Group, LLC | Nexus Pharmaceuticals, LLC | Release of Security Interest |
| Jun 3, 2024 reel/frame not recorded | Sagent Group, LLC | Nexpharm Parent Holdco, LLC | Release of Security Interest |
| Jun 3, 2024 reel/frame not recorded | Sagent Group, LLC | Isopro Holdings, LLC | Release of Security Interest |
| Jun 3, 2024 Reel 67600, frame 837 | Sagent Group, LLC | Nexus Pharmaceuticals, LLC; Nexpharm Parent Holdco, LLC; Isopro Holdings, LLC | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 11,478,436, ends no earlier than this term, so it caps nothing.